Target overview
Synonyms
c-MET|MET|hepatocyte growth factor receptor
Low Public Signal
c-MET / MET
c-MET / MET is flagged as low public signal based on 0 active trials across 0 sponsors and 2 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
Clinical activity
Public trial footprint
Clinical trials: 0
Active trials: 0
Recruiting trials: 0
Known assets: 0
Sponsor activity
Competitive footprint
Unique sponsors: 0
Top sponsors: Unknown
Tumor types: Unknown
Patent-density signal summary
Patent layer
Signal count: 2
Recent signals: 2
Top assignees: AstraZeneca | Zymeworks
Signal types: adc_composition
Scores and labels
Deterministic summary
Clinical crowding: 0/5 (Low)
Clinical maturity: 1/5 (Phase 1 Only)
Patent density: 1/5 (Low)
Momentum: 0/5 (Quiet)
Confidence: High
Limitations
Manual review still matters
This page summarizes public metadata patterns. It does not conclude patent scope, freedom to operate, clinical superiority, or commercial attractiveness.